Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 3:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-Small Cell Lung Cancer ALK-positive Clear all
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer
Interventions
Lorlatinib, Cisplatin or Carboplatin, Pemetrexed
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Denver, Colorado • Asheville, North Carolina • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Advanced NSCLC
Interventions
Brigatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Orange, California • Whittier, California • Pueblo, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced May 22, 2026, 3:48 AM EDT
No Longer Available No phase listed Expanded access
View directory record Official record
Conditions
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
49
States / cities
Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab, Carboplatin, Pemetrexed, Alectinib, Selpercatinib, Selumetinib, Etoposide, Cisplatin, Datopotamab deruxtecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced May 22, 2026, 3:48 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Ceritinib, Trametinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Davis, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
Interventions
Brigatinib, Crizotinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Sedona, Arizona • Bellflower, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Solid Tumor
Interventions
PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encinitas, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ceritinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 4 Interventional
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer, NSCLC
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Interventions
Neladalkib (NVL-655), Alectinib
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Glendale, Arizona • Newport Beach, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ceritinib, Pemetrexed, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
13
States / cities
Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 22, 2026, 3:48 AM EDT
Available No phase listed Expanded access
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
Interventions
Ensartinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions
Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
Other · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1613
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Interventions
PF-06463922, Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
32
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced May 22, 2026, 3:48 AM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Alectinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Orange, California • Atlanta, Georgia • Peoria, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 3:48 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Crizotinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced May 22, 2026, 3:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Thyroid Cancer
Interventions
Alectinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Irvine, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neoplasms
Interventions
Alectinib, Crizotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 3:48 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
X-396 (ensartinib), crizotinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Athens, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced May 22, 2026, 3:48 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Targeted Therapy, Nonsmall Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, ALK-positive Non-small Cell Lung Cancer, EGFR Positive Non-small Cell Lung Cancer, Palliative Care, Survivorship
Interventions
POISE
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 22, 2026, 3:48 AM EDT